<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166396</url>
  </required_header>
  <id_info>
    <org_study_id>HM20016707</org_study_id>
    <nct_id>NCT04166396</nct_id>
  </id_info>
  <brief_title>Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis</brief_title>
  <official_title>Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to examine if the use of antioxidant supplements
      impacts exercise intolerance in people with CF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exercise intolerance is a critical problem for people with cystic fibrosis (CF) able to
      predict hospitalization independent of lung function. Recent studies have suggested that
      certain supplements may help improving exercise intolerance.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 17, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Sirtuin1 (Sirt1)</measure>
    <time_frame>Change from baseline to up to 20 weeks</time_frame>
    <description>Sirt1 will be assessed via a standard assay from samples taken from the participant's vein</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>A: Cystic fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CF will be randomly assigned to resveratrol or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A: Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy controls will be randomly assigned to resveratrol or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Cystic Fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CF will be randomly assigned to NR or placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy controls will be randomly assigned to NR or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>500 mg resveratrol, BID</description>
    <arm_group_label>A: Cystic fibrosis</arm_group_label>
    <arm_group_label>A: Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NR</intervention_name>
    <description>500 mg NR BID</description>
    <arm_group_label>B: Cystic Fibrosis</arm_group_label>
    <arm_group_label>B: Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>A: Cystic fibrosis</arm_group_label>
    <arm_group_label>A: Healthy Controls</arm_group_label>
    <arm_group_label>B: Cystic Fibrosis</arm_group_label>
    <arm_group_label>B: Healthy Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        CF

          -  Diagnosis of CF

          -  Men and women (&gt; 18 yrs. old)

          -  FEV1 percent predicted &gt; 40%

          -  Patients with or without CF related diabetes

          -  Resting oxygen saturation (room air) &gt;90%

          -  Traditional CF-antioxidant medications

          -  Ability to perform reliable/reproducible PFTs

          -  Clinically stable for 4 weeks (no exacerbations or need for antibiotic antioxidant
             within 4 weeks of testing or major change in medical status)

          -  Pancreatic sufficient and pancreatic insufficient patients

        Exclusion Criteria:

        CF

          -  Children 17 years old and younger

          -  FEV1&lt;40% predicted

          -  Resting O2 saturation &lt;90%

          -  Clinical diagnosis of heart disease

          -  Clinical diagnosis of PAH

          -  Febrile illness within 4 weeks of a study visit

          -  Antioxidant for pulmonary exacerbation within 4 weeks of a study visit

          -  Currently smoking, pregnant or nursing

          -  Vasoactive medications (i.e. nitrates, beta-blockers, Viagra etc.)

          -  Patients with B. Cepacia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Rodriguez Miguelez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>resveratrol</keyword>
  <keyword>nicotinamide riboside</keyword>
  <keyword>exercise intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

